Skip to content

Study · Animal study (in vivo) · mouse · 2020

6 results

Anti-inflammatory effects of glycine thymosin β4 eye drops in experimental dry eye.

Jin R, Li Y, Li L, Kim DH, Yang CD, Son HS, Choi JH, Yoon HJ, Yoon KC

Biomedical reports2 Apr 2020Cited by 10 (Europe PMC)

PMID32382416 (opens in a new tab)PMCIDPMC7201140 (opens in a new tab)DOI10.3892/br.2020.1296 (opens in a new tab)PepBankPUB-32382416
Read at sourcePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In mice with experimental dry eye, all clinical parameters improved in the Gly-Tβ4 group (all P<0.05).

    In plain wordsIn mice with dry eye, Gly-Tβ4 eye drops improved all measured clinical signs of dry eye.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    Not applicableClinical parameters (tear volume, tear film break-up time, corneal staining)
    Study

    mousen: not reported in source

    Experimental dry eye
    Outcome group
    Ocular surface · Eye
    Studied dose
    0.1% · topical eye dropsAs given in this study (mouse).

    Source sentences

    Summary
    All clinical parameters showed improvement in the Gly-Tβ4 and CsA groups (all P<0.05).
    2 context sentences
    Summary · context
    Tear volume, tear film break-up time and corneal staining scores were measured after 7 and 14 days.
    Summary · context
    Eye drops consisting of balanced salt solution (BSS), 0.1% Gly-Tβ4 or 0.05% CsA were used for treatment of EDE.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In mice with experimental dry eye, Gly-Tβ4 significantly increased conjunctival goblet cells.

    In plain wordsIn mice with dry eye, Gly-Tβ4 eye drops increased the mucus-making goblet cells of the eye surface.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    IncreaseConjunctival goblet cells
    Study

    mousen: not reported in source

    Experimental dry eye
    Outcome group
    Ocular surface · Eye
    Studied dose
    0.1% · topical eye dropsAs given in this study (mouse).

    Source sentences

    Summary
    Significantly increased conjunctival gobleT cells and decreased corneal TUNEL positive cells were observed in the Gly-Tβ4 and CsA groups.
    1 context sentence
    Summary · context
    Eye drops consisting of balanced salt solution (BSS), 0.1% Gly-Tβ4 or 0.05% CsA were used for treatment of EDE.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In mice with experimental dry eye, Gly-Tβ4 significantly decreased corneal TUNEL-positive cells.

    In plain wordsIn mice with dry eye, Gly-Tβ4 eye drops reduced the number of dying cells in the cornea.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    DecreaseCorneal TUNEL-positive apoptotic cells
    Study

    mousen: not reported in source

    Experimental dry eye
    Outcome group
    Ocular surface · Eye
    Studied dose
    0.1% · topical eye dropsAs given in this study (mouse).

    Source sentences

    Summary
    Significantly increased conjunctival gobleT cells and decreased corneal TUNEL positive cells were observed in the Gly-Tβ4 and CsA groups.
    1 context sentence
    Summary · context
    Eye drops consisting of balanced salt solution (BSS), 0.1% Gly-Tβ4 or 0.05% CsA were used for treatment of EDE.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In mice with experimental dry eye, Gly-Tβ4 significantly reduced inflammatory cytokine levels in the conjunctiva compared with the EDE and BSS groups.

    In plain wordsIn mice with dry eye, Gly-Tβ4 eye drops lowered inflammatory cytokines compared with untreated and saline-treated dry eyes.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    DecreaseConjunctival inflammatory cytokine levels
    Study

    mousen: not reported in source

    Experimental dry eye
    Comparator
    EDE and BSS groups
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    0.1% · topical eye dropsAs given in this study (mouse).

    Source sentences

    Summary
    The Gly-Tβ4 and CsA treated groups showed significantly reduced inflammatory cytokine levels and T cells in the conjunctiva compared with the EDE and BSS groups (all P<0.05).
    2 context sentences
    Summary · context
    Periodic acid-Schiff staining for conjunctival gobleT cells, TUNEL assay for corneal apoptotic positive cells, multiplex immunobead assay for interleukin (IL)-1β, IL-6, tumor necrosis factor-α and interferon-γ levels, and flow cytometry for CD4+/CCR5+ T cells were performed after 14 days.
    Summary · context
    Eye drops consisting of balanced salt solution (BSS), 0.1% Gly-Tβ4 or 0.05% CsA were used for treatment of EDE.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In mice with experimental dry eye, Gly-Tβ4 significantly reduced T cells in the conjunctiva compared with the EDE and BSS groups.

    In plain wordsIn mice with dry eye, Gly-Tβ4 eye drops lowered T cell numbers compared with untreated and saline-treated dry eyes.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    DecreaseConjunctival CD4+/CCR5+ T cells
    Study

    mousen: not reported in source

    Experimental dry eye
    Comparator
    EDE and BSS groups
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    0.1% · topical eye dropsAs given in this study (mouse).

    Source sentences

    Summary
    The Gly-Tβ4 and CsA treated groups showed significantly reduced inflammatory cytokine levels and T cells in the conjunctiva compared with the EDE and BSS groups (all P<0.05).
    1 context sentence
    Summary · context
    Eye drops consisting of balanced salt solution (BSS), 0.1% Gly-Tβ4 or 0.05% CsA were used for treatment of EDE.
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In mice with experimental dry eye, inflammatory and clinical parameters did not differ significantly between Gly-Tβ4 and cyclosporine A.

    In plain wordsIn mice with dry eye, Gly-Tβ4 eye drops worked about as well as cyclosporine A drops on inflammation and clinical signs.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    No significant changeInflammatory and clinical parameters, Gly-Tβ4 versus cyclosporine A
    Study

    mousen: not reported in source

    Experimental dry eye
    Comparator
    Cyclosporine A 0.05%
    Outcome group
    Inflammation markers · Eye
    Studied dose
    0.1% · topical eye dropsAs given in this study (mouse).

    Source sentences

    Summary
    However, there were no significant differences observed in the inflammatory and clinical parameters between the Gly-Tβ4 and CsA treatment groups.
    1 context sentence
    Summary · context
    Eye drops consisting of balanced salt solution (BSS), 0.1% Gly-Tβ4 or 0.05% CsA were used for treatment of EDE.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 01:52 UTC

    Study results updated

  2. Version 1

    12 Oct 2026, 18:17 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.